Mechanisms of antidepressant action: An integrated dopaminergic perspective

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1532-1543

  Porcelli, S ^a   Drago, A ^a   Fabbri, C ^a   Serretti, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressant treatment; Dopamine; Inflammation; Major depressive disorder; Monoaminergic theory; Neurotrophin

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALMODULIN; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; IPRONIAZID; MIANSERIN; NEUROLEPTIC AGENT; NEUROTROPIN; NOMIFENSINE; OLANZAPINE; PINDOLOL; PROTEIN BCL 2; QUETIAPINE; RESERPINE; RISPERIDONE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; ZIPRASIDONE;

APOPTOSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN CONDENSATION; CYTOKINE RESPONSE; DNA MODIFICATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; DOPAMINE AGENTS; HUMANS; INFLAMMATION; NERVE GROWTH FACTORS;

EID: 79961127732     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.03.005     Document Type: Review

References (191)

1. Adachi M., Barrot M., Autry A.E., Theobald D., Monteggia L.M. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008, 63:642-649.
2. Akhtar R.S., Ness J.M., Roth K.A. Bcl-2 family regulation of neuronal development and neurodegeneration. Biochim Biophys Acta 2004, 1644:189-203.
3. Allain H., Schuck S., Mauduit N. Depression in Parkinson's disease. BMJ 2000, 320:1287-1288.
4. Alleva E., Della Seta D., Cirulli F., Aloe L. Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice. Prog Neuropsychopharmacol Biol Psychiatry 1996, 20:483-489.
5. Alme M.N., Wibrand K., Dagestad G., Bramham C.R. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation. Neural Plast 2007, 26,496.
6. Aloe L., Iannitelli A., Bersani G., Alleva E., Angelucci F., Maselli P., et al. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology 1997, 36:65-68.
7. Amore M., Jori M.C. Faster response on amisulpride 50mg versus sertraline 50-100mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001, 16:317-324.
8. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005, 15:311-317.
9. Angelucci F., Mathe A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000, 60:783-794.
10. Artigas F., Romero L., de Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996, 19:378-383.
11. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71:127-131.
12. Ballesteros J., Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004, 79:137-147.
13. Balu D.T., Hoshaw B.A., Malberg J.E., Rosenzweig-Lipson S., Schechter L.E., Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008, 1211:37-43.
14. Beck A., Rush A.J., Shaw B.F., Emery G. Cognitive therapy of depression 1979, New York.
15. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
16. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000, 62:63-88.
17. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994, 15:220-226.
18. Bolan E.A., Kivell B., Jaligam V., Oz M., Jayanthi L.D., Han Y., et al. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 2007, 71:1222-1232.
19. Bouras C., Kovari E., Hof P.R., Riederer B.M., Giannakopoulos P. Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol 2001, 102:373-379.
20. Bower G.H. Mood and memory. Am Psychol 1981, 36:129-148.
21. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115-118.
22. Brown A.S., Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993, 91:75-109.
23. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180.
24. Buss R.R., Sun W., Oppenheim R.W. Adaptive roles of programmed cell death during nervous system development. Annu Rev Neurosci 2006, 29:1-35.
25. Cabib S., Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl) 1996, 128:331-342.
26. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
27. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54:906-914.
28. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003, 160:1342-1345.
29. Capuron L., Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999, 340:1370.
30. Capuron L., Ravaud A., Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000, 18:2143-2151.
31. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7:468-473.
32. Carboni E., Silvagni A. Dopamine reuptake by norepinephrine neurons: exception or rule?. Crit Rev Neurobiol 2004, 16:121-128.
33. Carvey P.M., Chen E.Y., Lipton J.W., Tong C.W., Chang Q.A., Ling Z.D. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J Neural Transm 2005, 112:601-612.
34. Cassidy F., Weiner R.D., Cooper T.B., Carroll B.J. Combined catecholamine and indoleamine depletion following response to ECT. Br J Psychiatry 2010, 196:493-494.
35. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002, 954:11-20.
36. Chung Y.C., Ko H.W., Bok E., Park E.S., Huh S.H., Nam J.H., et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010, 43:225-232.
37. Collingridge G.L., Peineau S., Howland J.G., Wang Y.T. Long-term depression in the CNS. Nat Rev Neurosci 2010, 11:459-473.
38. Constant A., Castera L., Dantzer R., Couzigou P., de Ledinghen V., Demotes-Mainard J., et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005, 66:1050-1057.
39. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002, 12:386-394.
40. Czubak A., Nowakowska E., Kus K., Burda K., Metelska J., Baer-Dubowska W., et al. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 2009, 61:1017-1023.
41. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000, 405:365-373.
42. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004, 18:601-607.
43. Dantzer R., Bluthe R., Gheusi G., Cremona S., Laye S., Parnet P., et al. Molecular basis of sickness behavior. Ann NY Acad Sci 1998, 856:132-138.
44. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
45. Dawson N.M., Hamid E.H., Egan M.F., Meredith G.E. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001, 39:70-81.
46. DeCarolis N.A., Eisch A.J. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 2010, 58:884-893.
47. Di Giovanni G., Esposito E., Di Matteo V. Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther 2010, 16:179-194.
48. Dieperink E., Ho S.B., Tetrick L., Thuras P., Dua K., Willenbring M.L. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004, 26:237-240.
49. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213:93-118.
50. Drevets W.C., Price J.L., Simpson J.R., Todd R.D., Reich T., Vannier M., et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
51. Du F., Li R., Huang Y., Li X., Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 2005, 22:2422-2430.
52. Duman C.H., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 2007, 61:661-670.
53. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
54. Duman R.S., Malberg J., Nakagawa S., D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000, 48:732-739.
55. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
56. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
57. Dwivedi Y., Rizavi H.S., Pandey G.N. Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 2006, 139:1017-1029.
58. Ehmann T.S., Beninger R.J., Gawel M.J., Riopelle R.J. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990, 3:3-9.
59. Fibiger H.C. Neurobiology of depression: focus on dopamine. Adv Biochem Psychopharmacol 1995, 49:1-17.
60. Foley K.F., DeSanty K.P., Kast R.E. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006, 6:1249-1265.
61. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010, 167:388-396.
62. Friedman A., Deri I., Friedman Y., Dremencov E., Goutkin S., Kravchinsky E., et al. Decoding of dopaminergic mesolimbic activity and depressive behavior. J Mol Neurosci 2007, 32:72-79.
63. Glantz L.A., Gilmore J.H., Overstreet D.H., Salimi K., Lieberman J.A., Jarskog L.F. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res 2010, 118:292-299.
64. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007, 41:31-35.
65. Harlan J., Chen Y., Gubbins E., Mueller R., Roch J.M., Walter K., et al. Variants in Apaf-1 segregating with major depression promote apoptosome function. Mol Psychiatry 2006, 11:76-85.
66. Harmer C.J. Serotonin and emotional processing: does it help explain antidepressant drug action?. Neuropharmacology 2008, 55:1023-1028.
67. Harmer C.J., O'Sullivan U., Favaron E., Massey-Chase R., Ayres R., Reinecke A., et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 2009, 166:1178-1184.
68. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
69. Hauser P., Matochik J., Altshuler L.L., Denicoff K.D., Conrad A., Li X., et al. MRI-based measurements of temporal lobe and ventricular structures in patients with bipolar I and bipolar II disorders. J Affect Disord 2000, 60:25-32.
70. Heim C., Newport D.J., Mletzko T., Miller A.H., Nemeroff C.B. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008, 33:693-710.
71. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010, 36:472-485.
72. Henkel A.W., Sperling W., Rotter A., Reulbach U., Reichardt C., Bonsch D., et al. Antidepressant drugs modulate growth factors in cultured cells. BMC Pharmacol 2008, 8:6.
73. Herve D., Pickel V.M., Joh T.H., Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 1987, 435:71-83.
74. Hirayasu Y., Shenton M.E., Salisbury D.F., Kwon J.S., Wible C.G., Fischer I.A., et al. Subgenual cingulate cortex volume in first-episode psychosis. Am J Psychiatry 1999, 156:1091-1093.
75. Hyman SE, Nestler EJ. The molecular foundations of psychiatry. Washington D.C. 1993.
76. Jacobs B.L., van Praag H., Gage F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000, 5:262-269.
77. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell 1997, 88:347-354.
78. Jolas T., Haj-Dahmane S., Kidd E.J., Langlois X., Lanfumey L., Fattaccini C.M., et al. Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine. J Pharmacol Exp Ther 1994, 268:1432-1443.
79. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005, 162:1403-1413.
80. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57:1068-1072.
81. Katz N.S., Guiard B.P., El Mansari M., Blier P. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol 2010, 24:1223-1235.
82. Khundakar A.A., Zetterstrom T.S. Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res 2006, 1106:12-20.
83. King-Kallimanis B., Gum A.M., Kohn R. Comorbidity of depressive and anxiety disorders for older Americans in the national comorbidity survey-replication. Am J Geriatr Psychiatry 2009, 17:782-792.
84. Kinor N., Geffen R., Golomb E., Zinman T., Yadid G. Dopamine increases glial cell line-derived neurotrophic factor in human fetal astrocytes. Glia 2001, 33:143-150.
85. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation 2008, 5:8.
86. Kosten T.A., Galloway M.P., Duman R.S., Russell D.S., D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008, 33:1545-1558.
87. Kraus M.R., Schafer A., Faller H., Csef H., Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003, 64:708-714.
88. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
89. Lang U.E., Jockers-Scherubl M.C., Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J Neural Transm 2004, 111:387-411.
90. Le Poul E., Laaris N., Doucet E., Laporte A.M., Hamon M., Lanfumey L. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmiedebergs Arch Pharmacol 1995, 352:141-148.
91. Le Poul E., Lima L., Laporte A.M., Even C., Doucet E., Fattaccini C.M., et al. Encephale 1995, 21:123-132.
92. Lee B.H., Kim Y.K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology 2009, 59:51-58.
93. Lee H.J., Kim J.W., Yim S.V., Kim M.J., Kim S.A., Kim Y.J., et al. Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 2001, 6(610):725-728.
94. Lee S., Jeong J., Kwak Y., Park S.K. Depression research: where are we now?. Mol Brain 2010, 3:8.
95. Leppanen J.M. Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr Opin Psychiatry 2006, 19:34-39.
96. Licinio J., Wong M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999, 4:317-327.
97. Lisanby S.H., McDonald W.M., Massey E.W., Doraiswamy P.M., Rozear M., Boyko O.B., et al. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. J Neural Transm Suppl 1993, 40:13-21.
98. Lu X.H., Dwyer D.S. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005, 27:43-64.
99. Lucassen P.J., Fuchs E., Czeh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 2004, 55:789-796.
100. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995, 20:111-116.
101. Malhi G.S., Berk M. Does dopamine dysfunction drive depression?. Acta Psychiatr Scand Suppl 2007, 116-124.
102. Maris R.W. Suicide. Lancet 2002, 360:319-326.
103. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009, 43:247-254.
104. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000, 1:120-129.
105. Mayberg H.S., Starkstein S.E., Sadzot B., Preziosi T., Andrezejewski P.L., Dannals R.F., et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990, 28:57-64.
106. McClure D.J. The role of dopamine in depression. Can Psychiatr Assoc J 1973, 18:309,012.
107. McDonald W.M., Krishnan K.R. Magnetic resonance in patients with affective illness. Eur Arch Psychiatry Clin Neurosci 1992, 241:283-290.
108. McIntyre R.S., Muzina D.J., Kemp D.E., Blank D., Woldeyohannes H.O., Lofchy J., et al. Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep 2008, 10:66-72.
109. McKernan D.P., Dinan T.G., Cryan J.F. "Killing the Blues": a role for cellular suicide (apoptosis) in depression and the antidepressant response?. Prog Neurobiol 2009, 88:246-263.
110. Menza M.A., Mark M.H. Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 1994, 6:165-169.
111. Merikangas K.R., He J.P., Burstein M., Swanson S.A., Avenevoli S., Cui L., et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010, 49:980-989.
112. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007, 32:86-102.
113. Molander L., Randrup A. Effects of thymoleptics on behavior associated with changes in brain dopamine. II. Modification and potentiation of apomorphine-induced stimulation of mice. Psychopharmacology (Berl) 1976, 49:139-144.
114. Monteggia L.M., Barrot M., Powell C.M., Berton O., Galanis V., Gemelli T., et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004, 101:10,827-10,832.
115. Monteggia L.M., Luikart B., Barrot M., Theobold D., Malkovska I., Nef S., et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007, 61:187-197.
116. Moreno F.A., Parkinson D., Palmer C., Castro W.L., Misiaszek J., El Khoury A., et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur Neuropsychopharmacol 2010, 20:18-24.
117. Morice E., Billard J.M., Denis C., Mathieu F., Betancur C., Epelbaum J., et al. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 2007, 32:2108-2116.
118. Murray F., Hutson P.H. Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur J Pharmacol 2007, 569:41-47.
119. Nahon E., Israelson A., Abu-Hamad S., Varda S.B. Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett 2005, 579:5105-5110.
120. Nair V.D., Sealfon S.C. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem 2003, 278:47,053-47,061.
121. Nedergaard O.A. Catecholamines: regulation, release and inactivation. Pharmacol Toxicol 1988, 63(Suppl. 1):5-8.
122. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
123. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006, 59:1151-1159.
124. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15:7539-7547.
125. Nieoullon A., Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003, 16(Suppl. 2):S3-S9.
126. Ninan I., Bath K.G., Dagar K., Perez-Castro R., Plummer M.R., Lee F.S., et al. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci 2010, 30:8866-8870.
127. Nutt D.J., Baldwin D.S., Clayton A.H., Elgie R., Lecrubier Y., Montejo A.L., et al. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006, 67(Suppl. 6):46-49.
128. Obara Y., Nakahata N. The signaling pathway of neurotrophic factor biosynthesis. Drug News Perspect 2002, 15:290-298.
129. Ohta K, Kuno S, Inoue S, Ikeda E, Fujinami A, Ohta M. The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci 2010;291:12-6.
130. Oquendo M.A., Hastings R.S., Huang Y.Y., Simpson N., Ogden R.T., Hu X.Z., et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry 2007, 64:201-208.
131. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003, 37:43-51.
132. Parikh V., Khan M.M., Mahadik S.P. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004, 356:135-139.
133. Parikh V., Terry A.V., Khan M.M., Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology (Berl) 2004, 172:365-374.
134. Park S.W., Lee C.H., Lee J.G., Lee S.J., Kim N.R., Choi S.M., et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. J Psychiatr Res 2009, 43:274-281.
135. Park S.W., Lee J.G., Ha E.K., Choi S.M., Cho H.Y., Seo M.K., et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 2009, 19:356-362.
136. Parker K.J., Schatzberg A.F., Lyons D.M. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 2003, 43:60-66.
137. Pathania M., Yan L.D., Bordey A. A symphony of signals conducts early and late stages of adult neurogenesis. Neuropharmacology 2010, 58:865-876.
138. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006, 82:95-106.
139. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
140. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
141. Randrup A., Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 1977, 53:309-314.
142. Randrup A., Jonas W. Brain dopamine and the amphetamine-reserpine interaction. J Pharm Pharmacol 1967, 19:483-484.
143. Rantamaki T., Hendolin P., Kankaanpaa A., Mijatovic J., Piepponen P., Domenici E., et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007, 32:2152-2162.
144. Reichenberg A., Kraus T., Haack M., Schuld A., Pollmacher T., Yirmiya R. Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology 2002, 27:945-956.
145. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58:445-452.
146. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2010, 11:251-255.
147. Romero L., Hervas I., Artigas F. The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 1996, 219:123-126.
148. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12:331-359.
149. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003, 23:349-357.
150. Salgado-Pineda P., Delaveau P., Blin O., Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol 2005, 28:228-237.
151. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007, 10:1110-1115.
152. Schaefer M., Horn M., Schmidt F., Schmid-Wendtner M.H., Volkenandt M., Ackenheil M., et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 2004, 18:555-562.
153. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007, 62:55-64.
154. Shah P.J., Ebmeier K.P., Glabus M.F., Goodwin G.M. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998, 172:527-532.
155. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996, 93:3908-3913.
156. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
157. Shulman L.M., Taback R.L., Bean J., Weiner W.J. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001, 16:507-510.
158. Sinyor M., Schaffer A., Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry 2010, 55:126-135.
159. Smith R.S. The macrophage theory of depression. Med Hypotheses 1991, 35:298-306.
160. Stavrovskaya I.G., Narayanan M.V., Zhang W., Krasnikov B.F., Heemskerk J., Young S.S., et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med 2004, 200:211-222.
161. Tandberg E., Larsen J.P., Aarsland D., Laake K., Cummings J.L. Risk factors for depression in Parkinson disease. Arch Neurol 1997, 54:625-630.
162. Tansey M.G., McCoy M.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208:1-25.
163. Tanti A., Belzung C. Open questions in current models of antidepressant action. Br J Pharmacol 2010, 159:1187-1200.
164. Thase M.E. Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol 2006, 18:1213-1230.
165. Thornicroft G. Community supervision orders. BMJ 1993, 307:1213.
166. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000, 44:151-155.
167. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002, 110:249-257.
168. Tsai S.J., Hong C.J., Liou Y.J. Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics. Pharmacogenomics 2008, 9:1353-1358.
169. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007, 8:355-367.
170. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
171. Tsankova N.M., Kumar A., Nestler E.J. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci 2004, 24:5603-5610.
172. Valvassori S.S., Stertz L., Andreazza A.C., Rosa M.I., Kapczinski F., Streck E.L., et al. Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats. Metab Brain Dis 2008, 23:213-219.
173. Volkow N.D., Wang G.J., Fowler J.S., Tomasi D., Telang F., Baler R. Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuit. Bioessays 2010, 32:748-755.
174. Vucetic Z., Kimmel J., Totoki K., Hollenbeck E., Reyes T.M. Maternal high-fat diet alters methylation and gene expression of dopamine and opioid-related genes. Endocrinology 2010, 151:4756-4764.
175. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854.
176. Weaver I.C., Champagne F.A., Brown S.E., Dymov S., Sharma S., Meaney M.J., et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005, 25:11,045-11,054.
177. Wei Z., Mousseau D.D., Dai Y., Cao X., Li X.M. Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS. Pharmacogenomics J 2006, 6:279-288.
178. Weisler R.H., Calabrese J.R., Thase M.E., Arvekvist R., Stening G., Paulsson B., et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008, 69:769-782.
179. Wickens J. Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model. J Neural Transm Gen Sect 1990, 80:9-31.
180. Willner P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res 1983, 287:211-224.
181. Willner P. Dopamine and depression: a review of recent evidence. II. Theoretical approaches. Brain Res 1983, 287:225-236.
182. Willner P. Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res 1983, 287:237-246.
183. Wise R.A. Forebrain substrates of reward and motivation. J Comp Neurol 2005, 493:115-121.
184. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1508-1512.
185. Xu H., Chen Z., He J., Haimanot S., Li X., Dyck L., et al. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006, 16:551-559.
186. Xu H., Qing H., Lu W., Keegan D., Richardson J.S., Chlan-Fourney J., et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002, 321:65-68.
187. Xu H., Steven Richardson J., Li X.M. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003, 28:53-62.
188. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009, 14:51-59.
189. Yoshimura R., Hori H., Sugita A., Ueda N., Kakihara S., Umene W., et al. Treatment with risperidone for 4weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1072-1077.
190. Yoshimura R., Nakano Y., Hori H., Ikenouchi A., Ueda N., Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 2006, 21:433-438.
191. Yoshimura R., Ueda N., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010, 11:256-261.